major depressive disorder, Nasal Spray

FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
J&J’s ketamine-derived nasal spray approved by FDA to treat depression
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression.
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
WebMD10d
Living With Major Depressive Disorder
I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...
Using machine learning to predict how people diagnosed with major depressive disorder respond to treatment
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
Medscape8d
Largest Study to Date Identifies Hundreds of Genes for Major Depression
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
New Atlas1d
Popular exercise supplement may cut depression & enhance psychotherapy
A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.
Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
Psychology Today11h
When Politics and the Mind Collide
Explore how political divisiveness impacts mental health and amplifies high-functioning depression, and discover strategies ...
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...